Market Overview

Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday.

Universal Health Services

  • Universal Health Services, Inc. (NYSE: UHS)'s chief financial officer stated there hasn't been any notable fallout following a BuzzFeed article alleging improper clinical practices.
  • Repeal and Replace isn't expected to have any downside on the company's behavioral segment.
  • Repeal and Replace could spur growth in acute as states like Florida and Texas see increased funding for Medicaid expansion.
  • The analysts reiterated Universal Health as the top pick in the healthcare sector.

GW Pharmaceuticals

  • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s management team expressed their confidence that an NDA filing for the middle of 2017 for its Epidiolex therapy.
  • GW isn't certain if the U.S. Food and Drug Administration will hold a panel for Epidiolex but is preparing for one nevertheless.
  • GW continues to look for avenues for IP protection based on either earlier preclinical work or from the ongoing EAP study.

Related Link: Why Stocks Move When Execs Cancel Presentation Appearances


  • Celgene Corporation (NASDAQ: CELG)'s management believes that the current drug pricing environment demonstrates the need for companies to show a strong value proposition.
  • Management added that discussions with payers remain objective and constructive if a company can show the benefit to patients.
  • Shifting to company specific discussions, Celgene said that Revlimid is viewed as not a single asset but part of the myeloma franchise.
  • Celgene is targeting growth in every year through the 2020 to 2030 period.
  • Celgene said its 2020 guidance targets have been de-risked and will update its internal model "when they have data" to change the model.


  • Biogen Inc (NASDAQ: BIIB)'s management team said that its MS business is stable on a global volume basis.
  • Tecfidera is fully ramping up in many countries.
  • Biogen expects its Ocrevus therapy to compete directly with high-efficiency drugs such as Tysabri.
  • Biogen sees its recent settlement with Forward Pharma A/S (NASDAQ: FWP) as being more of an insurance policy against a worse-case outcome and not an admission of defeat.
  • Biogen confirmed that some payers are restricting access to its Spinraza therapy until more data is added to the label.

Posted-In: Analyst Color Biotech News Events Analyst Ratings Movers Trading Ideas General Best of Benzinga


Related Articles (BIIB + CELG)

View Comments and Join the Discussion!